GlassScriptPhysician profile
Christopher M Reeves
NPI 1396293114
$3,643.78
in general payments reported to CMS, 2019-2025
26 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,002 · 2022: $1,289 · 2023: $607 · 2024: $330 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $784.36 | 2022-2025 | Ajovy |
| Abbott Laboratories | $676.58 | 2021-2023 | Proclaim, Ionicrf |
| Abbvie INC. | $450.69 | 2021-2024 | |
| Pfizer INC. | $288.61 | 2023-2025 | |
| Medtronic, INC. | $199.84 | 2021-2025 | Inceptiv, Intellis Adaptivestim, Synchromedii |
| Biohaven Pharmaceuticals, INC. | $156.93 | 2021 | |
| Amgen INC. | $138.95 | 2021-2022 | |
| Almatica Pharma LLC | $128.38 | 2021 | |
| Nevro Corp. | $86.68 | 2021-2023 | Senza |
| Collegium Pharmaceutical, INC. | $80.00 | 2023-2024 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $78.48 | 2021-2023 | Ztlido |
| Boston Scientific Corporation | $76.30 | 2024-2025 | General - Pain Management |
| Novartis Pharmaceuticals Corporation | $65.25 | 2021 | |
| Ibsa Pharma INC. | $58.30 | 2021-2023 | Tirosint, Licart |
| Bioventus LLC | $51.86 | 2024-2025 | Supartz Fx Sodium Hyaluronate, Xcell |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $51.10 | 2022 | |
| Averitas Pharma INC. | $43.33 | 2023-2024 | Qutenza |
| Relievant Medsystems, INC. | $41.21 | 2022-2023 | Intracept |
| Grt US Holding, INC. | $38.31 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $32.09 | 2025 | |
| Allergan, INC. | $29.75 | 2021 | |
| Si-Bone, INC. | $21.92 | 2023 | |
| Fidia Pharma USA INC. | $20.38 | 2023 | Triluron, Hymovis |
| Lilly USA, LLC | $16.06 | 2021 | |
| Painteq LLC | $15.00 | 2023 | Painteq |
| Biodelivery Sciences International, INC. | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.